The combination of anti‐tumour strategies targeting RARs/RXRs with TNFAIP3 presents a novel avenue for managing ESCC, wherein ZSH‐2208 plays a pivotal role due to its inherent anti‐tumour activity and its potential to facilitate the development of innovative RA analogues in the anti‐tumour domain. This evidence concerns the gene RARS1 and esophageal squamous cell carcinoma.